Healthcare and Life Science
PhoreMost enters multi-project drug target discovery collaboration with Roche
PhoreMost to deploy its SITESEEKER platform to identify novel targets for Roche’s discovery programmes. ...
Guardtech going for gold at four awards evenings in space of four months
The cleanroom construction Group are up for five honours at glitzy showpieces in London and Cambridgeshire. ...
Avacta announces AVA6000 receives Orphan Drug Designation from the US Food and Drug Administration
London and Wetherby, UK - Avacta Group plc, a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, announces that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to...
Global Access Diagnostics acquires manufacturing rights for IT-LEISH rapid diagnostic test from Bio-Rad Laboratories
Bedford, UK - Global Access Diagnostics (GADx), a social enterprise prioritising equitable access to diagnostics and driving local manufacturing, announces it has acquired the manufacturing rights for the IT-LEISH rapid diagnostic test (RDT) for visceral leishmaniasis (VL) from Bio...
Why isn’t Adaptability more of a priority?
Well, when I put that question to the talented members of the Scottish Institute for Business Leaders this week, their wide-ranging and insightful answers included a clutch of stand-out insights: • It’s a complex concept • Too much energy is required • It’s not easy to...
Oxford Innovation Space appoints Gary Jennings as new Innovation Director at The Epicentre, Haverhill
Oxford Innovation Space has appointed Gary Jennings as the new Innovation Director at The EpiCentre in Haverhill alongside Centre Manager, Andrew Bell. Gary has many years’ experience of promoting healthcare businesses. “I am very pleased to be taking on this new role having worked in...
Avacta announces Phase I clinical study of AVA6000 to advance to the fourth cohort
London and Wetherby, UK - Avacta Group plc, a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, announces that the first-in-human Phase I trial (ALS-6000-101) of AVA6000 Pro-doxorubicin will advanc...
Hardware verification: are you meeting all your requirements?
Hardware verification provides evidence that a production representative sample of your medical device meets the issued hardware requirements. Unlike during software verification, which requires verification activities throughout the development, formal hardware verification is performe...
High-flying Guardtech prepare for string of international exhibitions
The cleanroom construction kings and queens are set for shows in Ireland, Germany and Singapore. ...
Bio-Rad introduces anti-evolocumab antibodies for use in preclinical and clinical drug development
HERCULES, Calif. — Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, introduces a range of type 1 antibodies that inhibit the binding of evolocumab (Repatha®) to its target, human proprotein convertase subtilisin/kexin type 9 (P...